Cancers · 2021 · 12 citations · 30 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer BiomarkersCancer ImmunotherapyImmune Checkpoint RegulationImmuno-oncology BiomarkersMolecular Tumor ProfilingTumor AntigensImmune Biomarkers In CancerImmune Checkpoint BiomarkersImmune Checkpoint LigandsImmunofluorescence AssaysImmunofluorescence ImagingIntratumoral Immune HeterogeneityMarker Expression PatternsProgrammed Death-ligand 1 Biomarker
CD200/CD200R is an immune checkpoint with broad expression patterns and a potential target for immune therapy. In this study, we assess both CD200 and CD200R expression in solid tumors, with a focus on lung cancer, and evaluate their association with clinicopathologic characteristics, mutation status, outcome, and programmed death-ligand 1 (PD-L1) expression. We used multiplexed quantitative immunofluorescence (QIF) to measure the expression of CD200 and CD200R in a total of 455 patients from three lung cancer cohorts. Using carefully validated antibodies, we performed target measurement with tyramide-based QIF panels and analyzed the data using the PM2000 microscope and AQUA software. CD200 tumor positivity was found in 29.7% of non-small cell lung cancer (NSCLC) patients and 33.3% of lung large cell neuroendocrine carcinoma (LCNEC) patients. CD200 demonstrated notable intratumoral heterogeneity. CD200R was expressed in immune cells in 25% of NSCLC and 41.3% of LCNEC patients. While CD200R is predominantly expressed in immune cells, rare tumor cell staining was seen in a highly heterogeneous pattern. CD200R expression in the stromal compartment was significantly higher in patients with squamous differentiation (p < 0.0001). Neither CD200 nor CD200R were associated with other clinicopathologic characteristics or mutation status. Both biomarkers were not prognostic for disease-free or overall survival in NSCLC. CD200 showed moderate correlation with PD-L1. CD200/CD200R pathway is frequently expressed in lung cancer patients. Differential expression patterns of CD200 and CD200R with PD-L1 suggest a potential role for targeting this pathway alone in patients with NSCLC.
30
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text
Medicine, Oncology, Pharmacology +16
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Ángel García-Díaz, Daniel Sanghoon Shin, Blanca Homet Moreno et al. · Cell Reports · 2017 · 1.9K citations · Full text
Life Sciences, Immunology, Oncology +17